Current Management of Persons with Myotonic Dystrophy Type 1
Nicholas Johnson, MD, Associate Professor in the Department of Neurology at Virginia Commonwealth University, explains myotonic dystrophy type 1 and how it is currently managed.
DM1 is a progressive neuromuscular disease caused by a triplet repeat in the DMPK gene.
Symptoms and severity are highly variable among patients, however, all forms of DM1 are associated with high levels of disease burden and may lead to premature mortality. Muscle weakness, cardiac conduction abnormalities, myotonia, cataracts, respiratory problems, fatigue, hypersomnia, severe gastrointestinal complications, and cognitive and behavioral impairment are some of the symptoms that can be present. Currently, there are no approved treatments for people with DM1.
Data from the phase 1/2 MARINA trial testing AOC 1001 in patients with DM1 was recently presented at the 75th American Academy of Neurology (AAN) Annual Meeting and showed the drug to be safe and effective. A Phase 3 clinical trial is currently being planned.
Watch video Current Management of Persons with Myotonic Dystrophy Type 1 online without registration, duration hours minute second in high quality. This video was added by user CheckRare 29 May 2023, don't forget to share it with your friends and acquaintances, it has been viewed on our site 1,02 once and liked it 1 people.